Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 6/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 6/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 6/20 | 0.41 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 5/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.38 |
| ▸ | NMT1 | P30419 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6309715 | 0.80 | CYP2D6 (0.39) | MEN1KMT2AGABRA1GABRG2GABRB3 | |
| SCHEMBL6311778 | 0.80 | MEN1 (0.46) | MEN1KMT2AGABRA1GABRG2GABRB3 | |
| SCHEMBL8591946 | 0.76 | MEN1 (0.43) | MEN1KMT2AGABRA1GABRG2GABRB3 | |
| SCHEMBL8819843 | 0.71 | SLC9A1 (0.42) | MEN1KMT2AGABRA1GABRG2GABRB3 | |
| SCHEMBL6312949 | 0.70 | SIGMAR1 (0.38) | SIGMAR1HTR2CCYP1A2CYP2D6TSHR | |
| SCHEMBL15186614 | 0.68 | CYP1A2 (0.38) | MEN1KMT2AGABRA1GABRG2GABRB3 | |
| SCHEMBL15450945 | 0.68 | CYP1A2 (0.51) | MEN1KMT2ACYP1A2CYP2D6TSHR | |
| SCHEMBL14045624 | 0.68 | CNR2 (0.46) | MEN1KMT2ACYP1A2CYP2D6TSHR | |
| SCHEMBL15186846 | 0.67 | CYP1A2 (0.34) | CYP1A2CYP2D6TSHRNFKB1HSD17B10 | |
| SCHEMBL15186636 | 0.67 | CYP1A2 (0.34) | MEN1KMT2ACYP1A2CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6844344-B2 | Benzofuran derivatives | ELI LILLY AND COMPANY (US) | 2005-01-18 | — | — | US | disclosed |
| US-6784180-B2 | INHIBITING THE REUPTAKE OF SEROTONIN AND ANTAGONIZING THE 5-HT1A RECEPTOR; AS ANTIDEPRESSANT OR TO POTENTIATE EFFECTS OF ANOTHER SSRI | ELI LILLY AND COMPANY | 2004-08-31 | — | — | US | disclosed |
| EP-1250336-B1 | PIPERIDINE DERIVATIVES AND THEIR USE AS SEROTONIN RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2004-05-12 | — | — | EP | disclosed |
| US-20030232833-A1 | Benzofuran derivatives | ELI LILLY AND COMPANY | 2003-12-18 | — | — | US | disclosed |
| US-20030225281-A1 | Piperidines derivatives and their use as serotonin receptor antagonists | ELI LILLY AND COMPANY | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225281-A1 | Piperidines derivatives and their use as serotonin receptor antagonists | HTR1A, HTR1D, HTR5A | MEN1 3722/4885KMT2A 2176/4885GABRA1 96/4885 |
| US-20030232833-A1 | Benzofuran derivatives | BRD1, BPTF, HTR1F | MEN1 4207/4885KMT2A 781/4885GABRA1 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.